A study by Sarich and colleagues (28) showed that canagliflozin increased 24 h urinary glucose excretion in a dose-dependent manner and reduced body weight but was not associated with meaningful changes in plasma glucose or insulin levels in adults with obesity but not diabetes. The gene discussed is INS; the disease is diabetes mellitus.